Skip to content

TScan Therapeutics, Inc.

TCRX Nasdaq SEC CIK 1783328

Follow TScan Therapeutics Weekly email: filings, results, news

News

3 stories filed under TScan Therapeutics, grouped into ongoing threads

TCRX discusses

Thread · 2 stories

TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study - Slideshow

Markets 20 d ago also on III

TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript

Markets 22 d ago also on III

More coverage

Tscan Therapeutics earnings beat by $0.03, revenue fell short of estimates

Earnings 43 d ago 3 sources

Profile

Headquarters: WALTHAM, MA, United States
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)

Peers

Where this page comes from

Profile · SEC EDGAR

News · 3 stories clustered from the RSS aggregator